Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

Cowen & Co. Maintains Outperform on Monday.Com, Raises Price Target to $180

By Benzinga Newsdesk

August 9, 10:27 AM

Cowen & Co. analyst J. Derrick Wood maintains Monday.Com (NASDAQ:MNDY) with a Outperform and raises the price target from $150 to $180.

MNDY

Levi Strauss Sees Gross Margin Expansion Of 0.2%-0.3% In 2023, Driven By Direct-To-Consumer Business, Digital, Women’s And International

By Michael Horton

January 25, 6:36 PM

-Reuters

LEVI

Shell To Acquire Pavilion Energy Assets From Temasek, Expanding LNG Market Reach In Europe And Singapore: Report

By Benzinga Neuro

June 13, 6:40 AM

Temasek Holdings is reportedly on the verge of sealing a deal with Shell for the sale of assets from its liquefied natural gas trading firm, Pavilion Energy.

SHEL

Piper Sandler Downgrades Change Healthcare to Neutral, Announces $27.75 Price Target

By Benzinga Newsdesk

September 20, 5:18 AM

Piper Sandler analyst Jessica Tassan downgrades Change Healthcare (NASDAQ:CHNG) from Overweight to Neutral and announces $27.75 price target.

CHNG

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Related Posts

Cowen & Co. Maintains Outperform on Monday.Com, Raises Price Target to $180

Levi Strauss Sees Gross Margin Expansion Of 0.2%-0.3% In 2023, Driven By Direct-To-Consumer Business, Digital, Women’s And International

Shell To Acquire Pavilion Energy Assets From Temasek, Expanding LNG Market Reach In Europe And Singapore: Report

Piper Sandler Downgrades Change Healthcare to Neutral, Announces $27.75 Price Target